托珠单抗治疗成人斯蒂尔病的长期安全性与有效性:III期试验开放标签长期扩展研究
该长期扩展研究纳入完成III期试验的22例成人斯蒂尔病患者,静脉给予托珠单抗8 mg/kg每2周一次。长期观察未发现新安全信号,疗效维持,ACR70应答率68.2%,糖皮质激素剂量较III期试验起始降低95.2%,40.9%达无激素缓解,63.6%患者成功延长给药间隔。
要点
- 长期使用托珠单抗未发现新的安全性信号。
- 疗效持续,ACR70应答率68.2%,CRP和铁蛋白控制良好。
- 糖皮质激素显著减量,40.9%患者达无激素缓解。
核心结论
- 长期使用托珠单抗未观察到新的安全性发现,应答持续且允许延长给药间隔并大幅减少或停用糖皮质激素。
研究设计与样本
- 为III期试验的开放标签长期扩展研究,纳入完成前序III期试验的22例成人斯蒂尔病患者,静脉给予托珠单抗8 mg/kg每2周一次直至日本获批,主要终点为安全性与耐受性。
主要发现
- 22例患者全部入组,16例(72.7%)完成长期扩展研究,平均观察期168.9±10.8周。
- 3例(13.6%)发生严重不良事件,导致2例退出试验,未检测到新安全信号。
- ACR70应答率为68.2%,糖皮质激素剂量较III期试验起始降低95.2%,末次访视无激素缓解率40.9%。
- CRP和铁蛋白等实验室指标保持良好控制,63.6%患者成功延长给药间隔,末次访视平均给药间隔3.4周。
关键数值与推荐
- ACR70应答率68.2%,糖皮质激素剂量降低95.2%,无激素缓解率40.9%,平均观察期168.9±10.8周。
- 63.6%患者成功延长给药间隔,末次访视平均托珠单抗给药间隔3.4周。
临床怎么用
- 支持托珠单抗长期用于成人斯蒂尔病以维持疗效并减少糖皮质激素用量。
- 长期治疗中可考虑个体化延长给药间隔。
局限性
- 为开放标签扩展研究,样本量小(22例),部分患者未完成长期扩展研究。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To investigate the long-term safety and efficacy of tocilizumab, an IL-6 receptor inhibitor, in patients with adult-onset Still's disease. METHODS: Patients who completed the precedent phase III trial of tocilizumab for adult-onset Still's disease were enrolled in a long-term extension (LTE) study. Patients received i.v. tocilizumab (8 mg/kg every 2 weeks) until its approval in Japan. The primary end point was safety and tolerability, and secondary endpoints included the ACR coreset response, glucocorticoid doses, tocilizumab dosing interval, remission defined as achieving ACR50 without fever and other laboratory parameters. Efficacy was assessed every 12 weeks. RESULTS: All 22 patients who had completed the precedent phase III trial participated in the LTE study. Sixteen (72.7%) completed the LTE study, with the mean observation period of 168.9 ± 10.8 weeks. Whereas three (13.6%) patients experienced serious adverse events, resulting in two patients withdrawn from the trial, no new safety signal was detected. Treatment efficacy was maintained through the LTE study, with the ACR70 response rate of 68.2% and 95.2% reduction in glucocorticoid doses from the start of the phase III trial and glucocorticoid-free remission of 40.9% at the last visit. Laboratory markers such as CRP and ferritin remained well controlled. The dosing interval was successfully extended in 63.6% of patients, with the overall mean tocilizumab interval at the final visit of 3.4 weeks. CONCLUSIONS: During the observation period, no new safety findings were observed with the long-term use of tocilizumab. Response to tocilizumab was sustained even with an extended dosing interval, with substantial glucocorticoid dose reduction or discontinuation. CLINICAL TRIAL REGISTRATION: UMIN000018414.
引用
- Suzuki K, Kameda H, Ikeda K, et al. Long-term safety and efficacy of tocilizumab in adult-onset Still's disease: open-label, long-term extension of the phase III trial. Rheumatology (Oxford). 2026. PMID: 41609432. doi:10.1093/rheumatology/keag054
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。